FDA Advisory Committees Would Get Patient Influence Under Hagan Bill
By
Derrick Gingery / Email the Author / “The Tan Sheet” Dec. 19, 2011, Vol. 19, No. 51
FDA / Word Count: 492 / Article # 05111212002
Executive Summary
Adjusting advisory committee conflict of interest rules becomes a high-priority issue in reauthorizing FDA’s drug user fee program. With several bills proposing to loosen the rules, Sen. Hagan’s draft FDA reform legislation could bring the most changes.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.